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Key points 
 While the World Health Organization recently recommended universal screening for HBV 
infection in all high-prevalence countries, there is an urgent need to document the proportion 
of HBV-infected patients in need of immediate treatment in sub-Saharan Africa 
 Our findings suggest that only a limited proportion (10%) of HBs antigen positive individuals 
are eligible for immediate antiviral therapy 
 Marked difference in treatment eligibility were reported across settings underlining the need 
for more studies on treatment eligibility to plan access to care in West Africa 
 Over half of patients were in need of close monitoring, supporting HBV universal testing and 
the need for prospective cohort studies 
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Abstract 
Background & Aims 
While universal screening of hepatitis B virus (HBV) is recommended in high burden countries, little 
is known about the proportion of HBV-infected persons in need of antiviral therapy in these settings. 
Methods 
Prisoners in Senegal and Togo, as well as female sex workers and men who have sex with men in 
Cote d’Ivoire were screened for HBV infection. All HBsAg-positive participants underwent transient 
elastography, alanine aminotransferase (ALT) and HBV viral load quantification. Individuals with 
liver cirrhosis or those aged>30 years with an HBV replication ≥20 000 IU/ml and elevated ALT were 
considered eligible for antiviral therapy. 
Results 
Of 1 256 participants, 110 (8.8%) were HBsAg-positive; their median age was 30 years [interquartile 
range: 25-33] and 96 (86.5%) were men. Three individuals (2.7%) had liver cirrhosis while 28 
(29.5%) of 94 participants with available measurements had an HBV viral load ≥20 000 IU/ml. 
Overall, 11 (10.0%) subjects were considered eligible for immediate antiviral treatment; 2.1% of 
participants in Dakar, 7.7% in Abidjan and 21.6% in Lome (p=0.001) and 59 (53.4%) for close 
monitoring due to the presence of significant liver fibrosis, elevated ALT or significant HBV 
replication. 
Conclusions 
Among vulnerable populations in West Africa, a minority of HBV-infected individuals were eligible 
for immediate antiviral therapy. Prospective cohort studies are necessary to evaluate anti-HBV 
treatment eligibility facing the significant proportion of individuals with active chronic HBV 
infection. 
Keywords: Hepatitis B virus, Antiviral treatment, Africa 
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Introduction 
Hepatitis B virus (HBV) infection is highly endemic in sub-Saharan Africa (SSA) and bears a 
high burden of liver disease (1). Despite the availability of an efficient vaccine against HBV 
infection, universal access to this prevention strategy is challenging in SSA (2). While HBV 
therapy is still out of reach for most HBV-infected individuals globally, progress towards 
universal access to these drugs is underway. Tenofovir disoproxil fumarate (TDF), an 
antiviral drug recommended and widely used in first-line treatment for HIV infection is also 
highly active against HBV infection and is now accessible as a generic drug at fairly low 
cost. Considering the new recommendations by the World Health Organization (WHO) to 
screen the general population for HBV infection in all high-prevalence countries, there is a 
need to document the proportion of HBV-infected patients in need of treatment (3). This is 
particularly true among vulnerable populations in West Africa where high HBV prevalence 
was previously reported (4). Our aim was to estimate the proportion of patients eligible for 
antiviral therapy among a sample of HBV-infected inmates, female sex workers (FSW) and 
men who have sex with men (MSM) in West Africa. 
Methods 
Study population and data collection 
We included all individuals diagnosed with an HBV infection in a cross-sectional prevalence 
study among vulnerable populations in West Africa. Inmates incarcerated in state prisons in 
Lome, Togo (September - October 2013) and Dakar, Senegal (April - May 2014) were 
initially recruited (5). FSW and MSM were subsequently recruited in a dedicated clinic 
located in Abidjan, Cote d’Ivoire (November 2014 – April 2015) (6). Inmates were randomly 
selected based on a cluster sampling approach using the prison cell as the statistical unit as 
previously described (5). FSW and MSM were randomly selected using a systematic 
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sampling approach. The sampling frame was the list of patients planned to attend the center 
on the days of inclusion. Considering a sampling interval k = number of participants to be 
included/number of people listed to attend, monitors were asked to select among the first k 
patients and consecutively include the following patients by applying this predetermined 
sampling interval. All participants were screened for HBV, hepatitis C virus (HCV) and HIV 
infection. If screened positive for HBV and/or HCV infection, participants were referred to a 
referent infectious disease unit in Lome, Dakar or Abidjan for a free specialized consultation. 
All HIV-infected participants were referred to the HIV national treatment facility but were 
excluded from the analysis. All participants provided a signed informed consent. The study is 
in compliance with the Helsinki Declaration and was approved by the national ethic 
committees of Côte d’Ivoire, Senegal and Togo. 
General characteristics 
Standardized questionnaires were administered in French or local language by nurses or site 
medical staff through face-to-face interviews. Socio-demographic data included age, sex and 
place of residence. Alcohol use was estimated using the Alcohol Use Disorders Identification 
Test (AUDIT) tool (7). We used the standard cut-off of 8 points to characterize hazardous 
drinking. Information on present or past history of injection drug use was also collected. 
Laboratory measurements 
Viral hepatitis infections were assessed using rapid diagnostic tests: Determine® (Alere, 
Waltham, MA, United States of America (USA)) for HBs antigen and Oraquick® (Orasure, 
Bethlehem, PA, USA) for anti-HCV antibodies (8). Anti-hepatitis delta virus (HDV) 
antibodies were measured with the ETI-AB-DELTA-2® (DiaSorin S.A., Antony, France). 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured and 
reported in international units (IU) per L. A high AST level was defined as a value >40 IU/L 
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and a high ALT level if ≥30 IU/L in men or ≥19 IU/L in women according to WHO 
recommendations (9). HBV viral load (VL) quantification was performed using the 
COBAS(R) AmpliPrep/COBAS(R) TaqMan(R) v2.0 (Roche®) kit in Dakar and Abidjan and 
the ABBOTT M2000RT (Abbot®) kit in Togo. An HBV VL≥2 000 IU/ml was considered 
clinically significant and a value ≥20 000 IU/ml a high viral load, as suggested in the 
European and WHO guidelines for the management of chronic HBV infection (9, 10). HBV 
genotype was determined using an in-house assay at the virology unit in Abidjan. 
Transient elastography 
All participants were assessed for liver fibrosis using a portable transient elastography device 
(Fibroscan 402®, Echosens, Paris) with an M probe. To be considered reliable, the 
examination had to include at least 10 valid measurements with an interquartile range (IQR) 
equal or below 30% of the median value [IQR/liver stiffness measurement (LSM) ≤30%] 
(11). We used cut-off values of LSM ≥7.9 kPa for significant fibrosis and ≥9.5 kPa for 
cirrhosis, as recently proposed in a validation study from The Gambia and Senegal (12). 
Treatment eligibility 
Based on the latest WHO recommendations, a simplified definition of treatment eligibility 
was applied to this HBV-infected population; patients presenting with cirrhosis using 
transient elastography or with an HBV VL ≥20 000 IU/ml combined with an abnormal ALT 
level) and aged >30 years were considered eligible, regardless of any other elements (9). 
Patients presenting at least one of the following elements; (i) HBV viral replication ≥2 000 
IU/ml, (ii) significant fibrosis (≥F2 METAVIR score based on transient elastography) (iii) 
abnormal ALT level were considered eligible for close monitoring. 
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Results 
Of the 1 396 pre-included participants (786 inmates, 610 FSW or MSM), 140 were excluded 
(refusal n=51, transferred or lost before the end of the study n=31, unreliable LSM n=25, 
indeterminate/unknown HBV, HCV or HIV status n=28 and age<18 years n=5). Of the 
remaining 1 256 included participants, infection with HBV was documented in 130 patients 
(10.3% [95% confidence interval (CI) 8.7 – 12.0]) with significant difference between Lome 
(10.9% [95% CI 7.7 – 14.2]), Dakar (14.1% [95% CI 10.4 – 17.8]) and Abidjan (7.8% [95% 
CI 5.6 – 10.0]) (p=0.01). Among HBV-infected patients, 20 subjects co-infected with HIV 
were excluded. 
A total of 110 HBV-infected patients were included; 37 in Lome, 47 in Dakar and 26 in 
Abidjan. Their median age was 30 years [interquartile range: 25-33] and 96 (86.5%) were 
men (Table 1, supporting information). A total of 46 (41.8%) subjects presented with an 
elevated ALT level, 11 (10.0%) with significant fibrosis and three (2.7%) with a cirrhosis. Of 
the 94 individuals with an available HBV VL, 28 (29.5%) had a value ≥20 000 IU/ml and 
nine (9.6%) a value between 2000 IU/ml and 20000 IU/ml. One patient tested positive for 
anti-HCV antibodies in Abidjan. 
Overall, 11 (10.0%) HBV-infected patients were considered eligible for immediate antiviral 
treatment (Figure 1). Anti-HBV treatment eligibility varied across countries with a proportion 
of 2.1% in Dakar, 7.7% in Abidjan and 21.6% in Lome (p=0.001). HBV treatment eligibility 
was more likely to be met by men (10.5%) compared to women (7.1%) although not 
significantly different (p=0.06). Overall, 59 (53.6%) subjects had a significant liver fibrosis 
and/or significant HBV viral replication and/or elevated ALT levels, classifying them as in 
need for a close monitoring of their HBV infection. 
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HBV genotype was characterized in 65 cases. Genotype E was the most frequent genotype 
identified (n=52), followed by genotype A (n=12) and genotype D (n=1) with significant 
differences across countries (Table 1). The 52 patients harboring HBV genotype E were 
significantly more likely to have a high HBV VL (≥20 000 IU/ml) compared to those with 
genotype A (50.0% vs. 16.7%, p=0.03). Eight (8.9%) of 89 patients tested for anti-HVD 
antibodies had a positive result. 
Discussion 
We provide one of few estimation of antiviral treatment eligibility among HBV-infected 
patients in SSA. Only 10% of HBsAg-positive participants were eligible for antiviral 
treatment based on WHO guidelines (9). However, over half of individuals had at least one 
criteria for close monitoring, which highlights the need for HBV screening in the general 
population of high-prevalence countries. 
Our HBV treatment eligibility estimates were consistent with those from a recent study 
conducted in the Gambia, where 4.4% of HBV-infected individuals from a community 
sample and 9.7% of blood donors were eligible for antiviral therapy (13). In our study, the 
proportion of individuals with a treatment indication was higher in Togo than in the other 
settings, mainly due to the high proportion of participants with a high HBV VL. Although the 
reason for this difference is unknown, a potential explanation could be the HBV genotype 
distribution: patients with genotype E were more likely to be eligible for anti-HBV treatment 
compared to those with a genotype A. As previously reported, genotype E was the most 
predominant type in the three participating countries (14). However, almost half of patients 
presented with a genotype A in Senegal, in line with previous reports (15, 16). Estimating the 
distribution of HBV genotypes has public health and clinical implications as previous reports 
identified HBV genotype as a predictor of clinical events (17). Over one-half of HBV-
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infected participants were in need of close monitoring, highlighting the need for larger, 
prospective assessments to document the dynamics of treatment eligibility over time. 
Our study population constituted of HBV-infected subjects screened among vulnerable 
populations may not be representative of the general population in West Africa. Although 
these groups were identified as vulnerable to viral hepatitis through high-risk sexual 
behaviors or intravenous drug use in high-income countries, HBV acquisition generally 
occurs at birth or during early childhood in SSA. In line with these observations, prevalence 
of HBV infection in our study was consistent with the prevalence in the general population 
from Cote d’Ivoire, Togo and Senegal (1). The lower prevalence of HBV-infected patients 
reported in Côte d’Ivoire was potentially related to demographic characteristics as the 
carriage of chronic HBs antigen was reported to be associated with male gender (13). The 
WHO recommendations used to assess treatment eligibility are a compromise based on 
limited access of diagnostic and treatment capacity. Therefore, the use of other international 
guidelines might provide significant differences in treatment eligibility. Applying the latest 
European guideline criteria for HBV treatment initiation resulted in seven patients (6.3%) 
eligible to immediate treatment, confirming the low rate of immediate treatment eligibility 
(10). The cross-sectional assessment of treatment eligibility might have led to the under-
estimation of the proportion of individuals eligible for antiviral therapy. For example, we 
were unable to assess the presence of persistent ALT elevation over time. 
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Conclusion 
In this sample of HBV-infected persons across West Africa only a minority were eligible to 
anti-HBV treatment but over half had signs of active infection. As access to antiviral 
treatment for HBV infection is likely to improve in highly endemic regions, better estimates 
of the true proportion of patients eligible to treatment from longitudinal studies are needed to 
inform policy and plan access to care.  
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Table 1. Characteristics of HBV-infected persons according to their place of residence (N=110). 
 
 
 Female sex workers/ MSM 
Abidjan (Ivory Coast) 
(n=26) 
Inmates 
Dakar (Senegal) 
(n=47) 
Inmates 
Lome (Togo) 
(n=37) 
p Total 
 
(n=110) 
Age (median, [IQR]), years 28.5 [24.5 – 32] 31 [26 – 37] 30 [26 – 32] 0.12 30 [25 -33] 
Gender 
 Men 
 Women 
 
12 (46.1) 
14 (53.9) 
 
47 (100.0) 
0 (0.0) 
 
37 (100.0) 
0 (0.0) 
<0.0001  
96 (87.3) 
14 (12.7) 
Alcohol use* 
 No/moderate use 
 Hazardous drinking 
 
23 (88.5) 
3 (11.5) 
 
44 (93.6) 
3 (6.4) 
 
33 (89.2) 
4 (10.8) 
0.69  
100 (90.9) 
10 (9.1) 
Intravenous drug use 
 Never 
 Present/past use 
 
26 (100.0) 
0 (0.0) 
 
46 (97.9) 
1 (2.1) 
 
37 (100.0) 
0 (0.0) 
0.89  
109 (98.9) 
1 (1.1) 
AST (IU/L), median, [IQR] 26 [20 – 34] 26 [22 – 36] 32.5 [28 – 42] 0.05 29 [22 – 38] 
AST**, n (%) (IU/L) 
 Normal 
 Elevated 
 
15 (57.7) 
11 (42.3) 
 
30 (63.8) 
17 (36.2) 
 
16 (43.2) 
21 (56.8) 
0.16  
61 (55.5) 
49 (44.5) 
ALT (IU/L), median, [IQR] 28.5 [18 – 40] 21 [16 – 31] 28.5 [21 – 35] 0.03 26 [18 – 35] 
ALT**, n (%) (IU/L) 
 Normal 
 Elevated 
 
9 (34.6) 
17 (65.4) 
 
35 (74.5) 
12 (25.5) 
 
20 (54.0) 
17 (46.0) 
0.003  
64 (58.2 
46 (41.8) 
Transient elastography (KPa) median, [IQR] 6.1 [5.0 – 6.8] 5.4 [4.8 – 6.6] 5.8 [4.9 – 6.9] 0.51 5.8 [4.9 – 6.7] 
Transient elastography† (KPa) 
 < 7.9 
 ≥ 7.9 – 9.5 
 ≥ 9.5 
 
24 (92.3) 
2 (7.7) 
0 (0.0) 
 
44 (93.6) 
2 (4.3) 
1 (2.1) 
 
31 (83.8) 
4 (10.8) 
2 (5.4) 
0.59  
99 (90.0) 
8 (7.3) 
3 (2.7) 
HBV viral load (n=94), n (%) IU/ml 
 < 2000 
 ≥ 2 000 - 20 000 
 ≥ 20 000 
 
21 (80.8) 
2 (7.7) 
3 (11.5) 
 
24 (77.4) 
2 (6.4) 
5 (16.2) 
 
12 (32.4) 
5 (13.5) 
20 (54.1) 
0.0003  
57 (60.6) 
9 (9.6) 
28 (29.8) 
HBV genotype (n=65), n (%) 
 A 
 D 
 E 
 
1 (7.1) 
0 (0.0) 
13 (92.9) 
 
10 (43.5) 
1 (4.3) 
12 (52.2) 
 
1 (3.6) 
0 (0.0) 
27 (96.4) 
0.001  
12 (18.5) 
1 (1.5) 
52 (80.0) 
Anti-HDV antibody (n=89), n (%) 
 Negative 
 Positive 
 
22 (88.0) 
3 (12.0) 
 
27 (93. 
2 (6.9) 
 
32 (91.4) 
3 (8.6) 
0.80  
81 (91.0) 
8 (9.0) 
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*Declared alcohol use during the last 12 month assessed with the Alcohol Use Disorders Identification Test (AUDIT), a threshold>8 was retained to define hazardous drinking **Threshold for 
high transaminase according to WHO guidelines: ALT≥30 IU/L in men or ≥19 IU/L in women, AST ≥40 IU/L †Threshold based on a validation study performed in the Gambia among HBV 
mono-infected patients (Lemoine et al. GUT, 2015). Abbreviations: IQR inter quartile range, AST aspartate aminotransferase, ALT alanine aminotransferase, HBV hepatitis B virus, HDV 
hepatitis D virus 
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Figure 1. Proportion of HBV-infected participants eligible for antiviral treatment or in 
need of close monitoring according to the WHO guidelines* in Lome (Togo), Dakar 
(Senegal) and Abidjan (Cote d’Ivoire) 2013-2015 (n=110). 
* Treatment eligible: patients presenting with cirrhosis (based on a transient elastography value ≥9.7 KPa) or an HBV viral 
load ≥20 000 IU/ml with an abnormal ALT (≥30 IU/L in men or ≥19 IU/L in women) if aged >30 years. Close monitoring 
considered if presence of at least one of the following elements; (i) HBV viral replication ≥2 000 IU/ml, (ii) significant 
fibrosis (≥F2 METAVIR score based on transient elastography) (iii) abnormal ALT level. Deferred treatment; none of the 
previous elements. 
†Men having sex with men, ‡Female sex workers, ∫Inmates  
 
 
 
 
 
